Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Aura Biosciences Inc ( (AURA) ) is now available.
On May 4, 2026, Aura Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 39,591,000 common shares and 3,800,000 pre-funded warrants, with underwriters exercising in full a 6,508,650-share option, and the offering closed on May 5, 2026. Priced at $6.00 per share and $5.99999 per pre-funded warrant, the deal generated approximately $280.8 million in net proceeds for the company.
Aura plans to allocate about $241.8 million of the proceeds, alongside existing cash, to advance its clinical programs, including in early choroidal melanoma, and to fund registration-enabling work for bel-sar, with remaining funds used for general corporate purposes. Around $39.0 million will go toward repurchasing 6,922,870 shares from Matrix Capital Management Master Fund LP, and the financing is expected to extend Aura’s cash runway to cover operating and capital needs into the second half of 2028, potentially strengthening its balance sheet and execution capacity for key oncology milestones.
The most recent analyst rating on (AURA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
The score is held back primarily by weak financial performance typical of a development-stage biotech (no revenue, widening losses, and rising cash burn), partially offset by a relatively low-debt balance sheet. Technicals are moderately constructive with the stock trading above major moving averages and positive MACD. Corporate events add support via late-stage trial progress and liquidity disclosures, while valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, including programs in early choroidal melanoma. Its pipeline includes bel-sar, for which it is pursuing registration-enabling activities, positioning the company within the niche market for innovative ocular cancer treatments and related oncology indications.
Average Trading Volume: 296,291
Technical Sentiment Signal: Buy
Current Market Cap: $536.1M
See more data about AURA stock on TipRanks’ Stock Analysis page.